Citations (45)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (9)
Nobuko Hijiya & Michael J Mauro. (2023) Asciminib in the Treatment of Philadelphia Chromosome-Positive Chronic Myeloid Leukemia: Focus on Patient Selection and Outcomes. Cancer Management and Research 15, pages 873-891.
Read now
Read now
Dayu Shi, Zongru Li, Yongjie Li & Qian Jiang. (2021) Variables associated with self-reported anxiety and depression symptoms in patients with chronic myeloid leukemia receiving tyrosine kinase inhibitor therapy. Leukemia & Lymphoma 62:3, pages 640-648.
Read now
Read now
Fabio Efficace, Alessandra Iurlo, Andrea Patriarca, Fabio Stagno, Ping-Chong Bee, Geneviève Ector, Isabella Capodanno, Chiara Elena, Massimiliano Bonifacio, Nicole M. A. Blijlevens, Giovanni Caocci, Chonghua Wan, Elisabetta Abruzzese, Massimo Breccia, Francesco Cottone, Iris Okumura, Simone Oerlemans, Nicola Cascavilla, Francesco Albano, Vamsi Kota, Monika Sztankay, Maria Cristina Miggiano, Susanne Saussele, Nicola Di Renzo, Federica Sorà, Fausto Castagnetti, Michele Baccarani, Marco Vignetti & Gianantonio Rosti. (2021) Validation and reference values of the EORTC QLQ-CML24 questionnaire to assess health-related quality of life in patients with chronic myeloid leukemia. Leukemia & Lymphoma 62:3, pages 669-678.
Read now
Read now
Nana Brochmann, Esben Meulengracht Flachs, Anne Illemann Christensen, Christen Lykkegaard Andersen, Knud Juel, Hans Carl Hasselbalch & Ann-Dorthe Zwisler. (2017) A nationwide population-based cross-sectional survey of health-related quality of life in patients with myeloproliferative neoplasms in Denmark (MPNhealthSurvey): survey design and characteristics of respondents and nonrespondents. Clinical Epidemiology 9, pages 141-150.
Read now
Read now
Federico De Marchi, Marta Medeot, Renato Fanin & Mario Tiribelli. (2017) How could patient reported outcomes improve patient management in chronic myeloid leukemia?. Expert Review of Hematology 10:1, pages 9-14.
Read now
Read now
Lauren Caldemeyer & Luke P. Akard. (2016) Rationale and motivating factors for treatment-free remission in chronic myeloid leukemia. Leukemia & Lymphoma 57:12, pages 2739-2751.
Read now
Read now
Massimo Breccia & Fabio Efficace. (2016) Health-related quality of life outcomes in chronic myeloid leukemia patients treated with second generation tyrosine kinase inhibitors: do we know enough?. Current Medical Research and Opinion 32:8, pages 1453-1454.
Read now
Read now
Massimo Breccia, Gioia Colafigli, Matteo Molica & Giuliana Alimena. (2016) Adverse events associated with tyrosine kinase inhibitors for the treatment of chronic myeloid leukemia. Expert Opinion on Drug Safety 15:4, pages 525-533.
Read now
Read now
Benedito A Carneiro, Jason B Kaplan & Francis J Giles. (2015) Tyrosine kinase inhibitor therapy in chronic myeloid leukemia: update on key adverse events. Expert Review of Hematology 8:4, pages 457-479.
Read now
Read now
Articles from other publishers (36)
Ann Hewison, Eve Roman, Alexandra Smith, Dorothy McCaughan, Rebecca Sheridan, Russell Patmore, Karl Atkin & Debra Howell. (2023) Chronic myeloid leukaemia: A qualitative interview study exploring disease impact from patient and practitioner perspectives. European Journal of Oncology Nursing 67, pages 102421.
Crossref
Crossref
Ann Hewison, Eve Roman, Alexandra Smith, Dorothy McCaughan, Rebecca Sheridan, Russell Patmore, Karl Atkin & Debra Howell. (2023) Chronic Myeloid Leukaemia: A Qualitative Study of Patient and Practitioner Experiences of Managing Treatment. European Journal of Cancer Care 2023, pages 1-12.
Crossref
Crossref
Gianantonio Rosti, Tim H. Brümmendorf, Björn T. Gjertsen, Pilar Giraldo-Castellano, Fausto Castagnetti, Carlo Gambacorti-Passerini, Thomas Ernst, Huadong Zhao, Luke Kuttschreuter, Simon Purcell, Francis J. Giles & Andreas Hochhaus. (2023) Impact of age and comorbidities on the efficacy and tolerability of bosutinib in previously treated patients with chronic myeloid leukemia: results from the phase 4 BYOND study. Leukemia.
Crossref
Crossref
Yolba Smit, Sanne J J P M Metsemakers, Jeroen J W M Janssen, Eduardus F M Posthuma, Iris Walraven, Rosella P M G Hermens & Nicole M A Blijlevens. (2023) Measuring chronic myeloid leukaemia TKI-related toxic effects in the real world: a systematic review and critical assessment of content validity of patient-reported outcome measures. The Lancet Haematology.
Crossref
Crossref
Yilin Chen, Na Xu, Yunfan Yang, Zhenfang Liu, Mengxing Xue, Li Meng, Qun He, Chunyan Chen, Qingshu Zeng, Huanling Zhu, Xin Du, Jing Zou, Wenjun He, Jingming Guo, Suning Chen, Guolin Yuan, Hui Wu, Mei Hong, Fanjun Cheng, Bingcheng Liu, Yanli Zhang & Weiming Li. (2023)
Quality‐of‐life, mental health, and perspective on
TKI
dose reduction as a prelude to discontinuation in chronic phase chronic myeloid leukemia
. Cancer Medicine 12:16, pages 17239-17252.
Crossref
Crossref
Paola Pacelli, Adele Santoni, Anna Sicuranza, Elisabetta Abruzzese, Valentina Giai, Monica Crugnola, Mario Annunziata, Sara Galimberti, Alessandra Iurlo, Luigiana Luciano, Federica Sorà, Carmen Fava, Elena Bestoso, Cristina Marzano, Alessandra Cartocci, Marzia Defina, Vincenzo Sammartano, Emanuele Cencini, Donatella Raspadori & Monica Bocchia. (2023) Prospective monitoring of chronic myeloid leukemia patients from the time of TKI discontinuation: the fate of peripheral blood CD26+ leukemia stem cells. Frontiers in Pharmacology 14.
Crossref
Crossref
Melissa F Djodikromo, Rosella PMG Hermens, Bart JF van den Bemt, Yolba Smit, Tim M Govers, Charlotte L Bekker & Nicole MA Blijlevens. (2023) Patient-guided dose reduction of tyrosine kinase inhibitors in chronic myeloid leukaemia (RODEO study): study protocol for a prospective, multicentre, single-arm trial. BMC Cancer 23:1.
Crossref
Crossref
Antonio E. Nardi, Federica Sancassiani, Vanessa Barrui, Goce Kalcev, Veronica Uras, Giulia Meloni, Luigi Marongiu, Giorgio Tamburini, Alberto Maleci, Laiana A. Quagliato, Giorgio La Nasa & Mauro Giovanni Carta. (2023) The Effects of Tyrosine Kinase Inhibitors (TKIs) in Monotherapy and with Add-on Treatments on Health-related Quality of Life of People with Chronic Myeloid Leukemia: A Systematic Review of Randomized-Controlled Trials. Clinical Practice & Epidemiology in Mental Health 19:1.
Crossref
Crossref
Kelly L. Schoenbeck & Kathryn E. Flynn. (2021) Health-Related Quality of Life of Patients with Chronic Myeloid Leukemia as Measured by Patient-Reported Outcomes: Current State and Future Directions. Current Hematologic Malignancy Reports 16:6, pages 491-499.
Crossref
Crossref
Sharifa Ezat Wan Puteh, Azimatun Noor Aizuddin, Nor Rafeah Tumian, Jameela Sathar & Ellyana Mohamad Selamat. (2021) Health-related quality of life using EQ-5D among chronic myeloid leukaemia patients in health centres in Klang Valley, Malaysia. PLOS ONE 16:8, pages e0256804.
Crossref
Crossref
Hilbeen Hisham Saifullah & Claire Marie Lucas. (2021) Treatment-Free Remission in Chronic Myeloid Leukemia: Can We Identify Prognostic Factors?. Cancers 13:16, pages 4175.
Crossref
Crossref
Samantha C. Sodergren, Sally J. Wheelwright, Deborah Fitzsimmons, Fabio Efficace, Mirjam Sprangers, Peter Fayers, Amelie Harle, Heike Schmidt, Andrew Bottomley, Anne-Sophie Darlington, Charlotte Benson, Anne Bredart, Leopold Hentschel, Juan Ignacio Arraras, Georgios Ioannidis, Michael Leahy, Iwona Lugowska, Ourania Nicolatou-Galitis, Duska Petranovic, Gudrun E Rohde, Vasilis Vassiliou & Colin D. Johnson. (2020) Developing Symptom Lists for People with Cancer Treated with Targeted Therapies. Targeted Oncology 16:1, pages 95-107.
Crossref
Crossref
Ruth Stuckey, Juan Francisco López-Rodríguez, Santiago Sánchez-Sosa, Adrián Segura-Díaz, Nuria Sánchez-Farías, Cristina Bilbao-Sieyro & María Teresa Gómez-Casares. (2020) Predictive indicators of successful tyrosine kinase inhibitor discontinuation in patients with chronic myeloid leukemia. World Journal of Clinical Oncology 11:12, pages 996-1007.
Crossref
Crossref
Christel C. L. M. Boons, Lonneke Timmers, Jeroen J. W. M. Janssen, Peter E. Westerweel, Nicole M. A. Blijlevens, Willem M. Smit, Imke H. Bartelink, Janneke A. Wilschut, Eleonora L. Swart, N. Harry Hendrikse & Jacqueline G. Hugtenburg. (2020) Response and Adherence to Nilotinib in Daily practice (RAND study): an in-depth observational study of chronic myeloid leukemia patients treated with nilotinib. European Journal of Clinical Pharmacology 76:9, pages 1213-1226.
Crossref
Crossref
Jeff P. Sharman, Kim Cocks, Chadi Nabhan, Nicole Lamanna, Neil E. Kay, David L. Grinblatt, Christopher R. Flowers, Matthew S. Davids, Pavel Kiselev, Arlene S. Swern, Kristen Sullivan, Mecide M. Gharibo, E. Dawn Flick, Andrew Trigg & Anthony Mato. (2020)
Longitudinal health‐related quality of life in first‐line treated patients with chronic lymphocytic leukemia: Results from the Connect
®
CLL Registry
. eJHaem 1:1, pages 188-198.
Crossref
Crossref
Tim H. Brümmendorf, Carlo Gambacorti-Passerini, Andrew G. Bushmakin, Joseph C. Cappelleri, Andrea Viqueira, Arlene Reisman, Susanne Isfort & Carla Mamolo. (2020) Relationship between molecular response and quality of life with bosutinib or imatinib for chronic myeloid leukemia. Annals of Hematology 99:6, pages 1241-1249.
Crossref
Crossref
Hélène Haguet, Carlos Graux, François Mullier, Jean-Michel Dogné & Jonathan Douxfils. (2020) Long-Term Survival, Vascular Occlusive Events and Efficacy Biomarkers of First-Line Treatment of CML: A Meta-Analysis. Cancers 12:5, pages 1242.
Crossref
Crossref
Lu Yu, Xiaojun Huang, Robert Peter Gale, Haibo Wang & Qian Jiang. (2019) Variables associated with patient-reported symptoms in persons with chronic phase chronic myeloid leukemia receiving tyrosine kinase inhibitor therapy. Medicine 98:48, pages e18079.
Crossref
Crossref
Lu Yu, Haibo Wang, Darko Milijkovic, Xiaojun Huang & Qian Jiang. (2018) Achieving optimal response at 12 months is associated with a better health-related quality of life in patients with chronic myeloid leukemia: a prospective, longitudinal, single center study. BMC Cancer 18:1.
Crossref
Crossref
Ami B. Patel, Thoralf Lange, Anthony D. Pomicter, Christopher J. Conley, Christina A. Harrington, Kimberly R. Reynolds, Todd W. Kelley, Thomas O’Hare & Michael W. Deininger. (2018) Similar expression profiles in CD34+ cells from chronic phase chronic myeloid leukemia patients with and without deep molecular responses to nilotinib. Oncotarget 9:25, pages 17889-17894.
Crossref
Crossref
Devendra Hiwase, Peter Tan, James D’Rozario, John Taper, Anthony Powell, Ian Irving, Matthew Wright, Susan Branford, David T. Yeung, Luke Anderson, Othon Gervasio, Carly Levetan, Will Roberts, Ann Solterbeck, Robert Traficante & Timothy Hughes. (2018) Efficacy and safety of nilotinib 300 mg twice daily in patients with chronic myeloid leukemia in chronic phase who are intolerant to prior tyrosine kinase inhibitors: Results from the Phase IIIb ENESTswift study. Leukemia Research 67, pages 109-115.
Crossref
Crossref
Qian Jiang, Haibo Wang, Lu Yu & Robert Peter Gale. (2017) Higher out-of-pocket expenses for tyrosine kinase-inhibitor therapy is associated with worse health-related quality-of-life in persons with chronic myeloid leukemia. Journal of Cancer Research and Clinical Oncology 143:12, pages 2619-2630.
Crossref
Crossref
Ravi Kishore Narra, Kathryn E. Flynn & Ehab Atallah. (2017) Chronic Myeloid Leukemia—the Promise of Tyrosine Kinase Inhibitor Discontinuation. Current Hematologic Malignancy Reports 12:5, pages 415-423.
Crossref
Crossref
Qian Jiang, Hai-Bo Wang, Lu Yu & Robert Peter Gale. (2017) Variables associated with patient-reported outcomes in persons with chronic myeloid leukemia receiving tyrosine kinase-inhibitor therapy. Journal of Cancer Research and Clinical Oncology 143:6, pages 1013-1022.
Crossref
Crossref
Giuseppe Tridente. 2017. Adverse Events and Oncotargeted Kinase Inhibitors. Adverse Events and Oncotargeted Kinase Inhibitors
695
705
.
Giuseppe Tridente. 2017. Adverse Events and Oncotargeted Kinase Inhibitors. Adverse Events and Oncotargeted Kinase Inhibitors
265
281
.
Giuseppe Tridente. 2017. Adverse Events and Oncotargeted Kinase Inhibitors. Adverse Events and Oncotargeted Kinase Inhibitors
199
219
.
Giuseppe Tridente. 2017. Adverse Events and Oncotargeted Kinase Inhibitors. Adverse Events and Oncotargeted Kinase Inhibitors
97
122
.
Francisco Cervantes, Juan-Gonzalo Correa, Isabel Pérez, Valentín García-Gutiérrez, Sara Redondo, Dolors Colomer, Antonio Jiménez-Velasco, Juan-Luis Steegmann, Fermín Sánchez-Guijo, Francisca Ferrer-Marín, Arturo Pereira & Santiago Osorio. (2016) Imatinib dose reduction in patients with chronic myeloid leukemia in sustained deep molecular response. Annals of Hematology 96:1, pages 81-85.
Crossref
Crossref
Fabio Efficace & Laura Cannella. (2016) The value of quality of life assessment in chronic myeloid leukemia patients receiving tyrosine kinase inhibitors. Hematology 2016:1, pages 170-179.
Crossref
Crossref
Fabio Efficace, Massimo Breccia, Francesco Cottone, Iris Okumura, Maribel Doro, Francesca Riccardi, Gianantonio Rosti & Michele Baccarani. (2016) Psychological well-being and social support in chronic myeloid leukemia patients receiving lifelong targeted therapies. Supportive Care in Cancer 24:12, pages 4887-4894.
Crossref
Crossref
Stéphanie Dulucq & Francois‐Xavier Mahon. (2016) Deep molecular responses for treatment‐free remission in chronic myeloid leukemia. Cancer Medicine 5:9, pages 2398-2411.
Crossref
Crossref
Kendra Sweet & Javier Pinilla-Ibarz. (2016) Early switch in tyrosine kinase inhibitor therapy for patients with chronic myeloid leukemia: An emerging clinical question. Critical Reviews in Oncology/Hematology 103, pages 99-108.
Crossref
Crossref
Jorge E. Cortes, Jeffrey H. Lipton, Carole B. Miller, Lambert Busque, Luke P. Akard, Javier Pinilla-Ibarz, Christopher Keir, Ghulam Warsi, Felice P. Lin & Michael J. Mauro. (2016) Evaluating the Impact of a Switch to Nilotinib on Imatinib-Related Chronic Low-Grade Adverse Events in Patients With CML-CP: The ENRICH Study. Clinical Lymphoma Myeloma and Leukemia 16:5, pages 286-296.
Crossref
Crossref
Kathryn E. Flynn & Ehab Atallah. (2016) Quality of Life and Long-Term Therapy in Patients with Chronic Myeloid Leukemia. Current Hematologic Malignancy Reports 11:2, pages 80-85.
Crossref
Crossref
Noriaki Kawano, Shuro Yoshida, Sayaka Kawano, Takuro Kuriyama, Kiyoshi Yamashita, Hidenobu Ochiai, Kazuya Shimoda, Fumihiko Ishikawa, Akira Ueda & Ikuo Kikuchi. (2016) Clinical Features and Treatment Outcomes of 51 Patients with Chronic Myeloid Leukemia Treated with a Tyrosine Kinase Inhibitor at a Single Institution from 2002 to 2014. Journal of Clinical and Experimental Hematopathology 56:1, pages 34-42.
Crossref
Crossref